Story
Grand Pharma's Cancer Diagnostic GPN01530-2 Receives FDA Fast Track Designation

Grand Pharmaceutical (00512.HK) announced its internally developed, innovative radiopharmaceutical drug conjugate (RDC), GPN01530-2, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designation is for the drug's use in diagnosing solid tumors.
Designation to Expedite Development
The FDA's Fast Track program is designed to facilitate the development and hasten the review of drugs intended to treat serious conditions and fill an unmet medical need. According to the company's announcement, this designation allows for more frequent communication with the FDA and eligibility for Accelerated Approval and Priority Review, if relevant criteria are met.
The status also permits a rolling review of the New Drug Application (NDA), enabling the company to submit completed sections for review rather than waiting for the entire application to be finished. GPN01530-2 had previously received FDA clearance to proceed with Phase I/II clinical trials in the United States.
A Novel Imaging Agent
GPN01530-2 is a small-molecule RDC that targets Fibroblast Activation Protein (FAP), a protein highly expressed in over 90% of epithelial tumors but found at low levels in healthy tissue, making it a promising target for cancer diagnosis and therapy. The drug is positioned as a potential improvement over the current standard PET/CT imaging agent, 18F-FDG, which the company notes has relatively low sensitivity.
AdGrand Pharma stated that preclinical and early human investigator-initiated studies showed GPN01530-2 has a good safety profile, rapid tumor targeting, and superior pharmacokinetic properties. The company reported that the agent demonstrated better clinical image contrast and more accurate detection of positive lesions compared to 18F-FDG.
Market Context and Strategy
This regulatory milestone supports Grand Pharma's global expansion in the nuclear medicine and anti-tumor sector, which utilizes a "US-China dual filing" international registration strategy. The global market for radiopharmaceuticals is projected to grow from $9.7 billion in 2024 to $57.3 billion by 2035, according to market data cited by the company, driven by technological advances and an aging population.
The company has established a significant presence in the field, with a pipeline of 16 innovative RDC and interventional oncology products. It recently completed a new radiopharmaceutical R&D and production base in Chengdu, China, which it describes as a platform covering the entire industry chain from isotope preparation to commercialization.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.